Drug Profile
Research programme: biosimilars - Polpharma Biologics
Alternative Names: BC 004; BC 006; BC 008; BC 009; BC 011; BC 012; BC 013; BC 014Latest Information Update: 16 Jul 2020
Price :
$50
*
At a glance
- Originator Bioceros
- Developer EPIRUS Biopharmaceuticals
- Class Enzymes; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 13 Jul 2020 Polpharma Biologics acquired Bioceros and changed name to Polpharma Biologics
- 28 Jul 2019 No recent reports of development identified for research development in Unspecified in Netherlands
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)